Research Advancements on Programmed Cell Death in Lung Ischemia Reperfusion Injury
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2025.0606
- VernacularTitle:程序性细胞死亡在肺缺血再灌注损伤中的研究进展
- Author:
Yanqing YU
1
;
Xuyong SUN
2
Author Information
1. Department of Immunology， School of Basic Medical Sciences， Guangxi Medical University， Nanning 530021， China
2. Institute of Transplant Medicine， The Second Affiliated Hospital of Guangxi Medical University// Guangxi Clinical Research Center for Organ Transplantation//Guangxi Key Laboratory of Organ Donation and Transplantation， Nanning 530007， China
- Publication Type:Review
- Keywords:
lung ischemia reperfusion injury;
apoptosis;
necroptosis;
autophagy;
ferroptosis;
pyroptosis;
cuproptosis
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2025;46(6):964-972
- CountryChina
- Language:Chinese
-
Abstract:
Lung transplantation （LTx） is the only effective curative treatment for end-stage lung disease （ESLD）， applicable to patients with advanced lung diseases who do not respond to medical and other surgical management， and can significantly improve the prognosis. However， LTx still faces many challenges， such as ischemia-reperfusion injury （IRI） and low long-term survival. Improving lung IRI is of great significance for the recovery of lung function and the prognosis of patients after transplantation. Lung IRI is a response to tissue damage and inflammation that worsens when the blood supply to the lung tissue is restored （reperfusion） after it has undergone a disruption of blood flow （ischemia）. IRI is an important pathophysiological basis for primary graft dysfunction （PGD）， and its injury mechanisms are complex and diverse， involving the activation of multiple cell deaths. Programmed cell death （PCD） is a highly ordered process of cell self-extinction regulated by genes， mainly including apoptosis， necroptosis， autophagy， ferroptosis， pyroptosis and cuproptosis， which are of great physiological significance for maintaining biological development， homeostasis and immune defense. Recent studies have shown that the activation of multiple PCDs is closely related to the occurrence and development of lung IRI. PCD is widely involved in lung IRI through different molecular mechanisms， but its specific regulatory mechanism has not been fully elucidated. This article systematically reviews the latest progress of various types of PCD in lung IRI， analyzes the molecular mechanism and interaction of PCD in lung IRI， and explores their potential as therapeutic targets， aiming to provide new insights for the development of clinical lung protection strategies.
